Access to the latest research — for scientists and people living with PD alike — in PDF's new scientific journal.
Cephalon and H. Lundbeck Announce Discontinuation of CEP-1347 Clinical Trial in Parkinson's Disease
- May 11 2005
Cephalon, Inc. and H. Lundbeck A/S announced today the discontinuation of their Phase 2/3 clinical trial of CEP-1347 in Parkinson's disease. An independent data monitoring committee just completed a planned review of interim results and concluded that the data are unlikely to provide evidence of significant effect. There were no safety concerns.
The study was being conducted by the Parkinson Study Group, a non-profit, cooperative group of Parkinson's disease experts from medical centers in the United States and Canada who are dedicated to improving treatment for persons affected by Parkinson's disease.
"While we are disappointed with results of the trial, our collaboration with Lundbeck will continue as a valuable part of our ongoing research program in neurodegenerative disorders," said Dr. Jeffry L. Vaught, Senior Vice President and President, Research and Development at Cephalon. "We will continue to actively evaluate compounds for further clinical development with Lundbeck."
Source Date: May 11 2005
Source Publication: Cephalon, Inc.
View source URL